Lorraine L. Katz, MD, is an attending physician at Children’s Hospital of Philadelphia who cares for children with diabetes, hyperinsulinism, 22q11.2 deletion syndrome and other conditions.
Areas of Expertise:
Pediatric type 2 diabetes, Risk for pediatric type 1 and type 2 diabetes, 22q11.2 Deletion Syndrome, Growth and endocrine disorders in children, Hyperinsulinism Locations:Specialty Care, Virtua; Main Hospital
Dr. Katz received her BA with honors from Barnard College/Columbia University and her MD from the University of Connecticut School of Medicine where she was awarded the Linda Ives prize for Pediatric Research and was designated a Scholar in Pediatrics. She completed her pediatric residency at Babies Hospital of Columbia University and fellowship training at The Children’s Hospital of Philadelphia. During fellowship, she received the prestigious Lawson Wilkins Pediatric Endocrine Society Award to support her research as well as the Society for Pediatric Research Fellow’s Clinical Research Award.
In 1996, Dr. Katz was appointed to Assistant Professor of Pediatrics and attending physician in the Division of Endocrinology. She successfully obtained an NIH GCRC Clinical Associate Physician (CAP) Award and subsequently has served as the CHOP Principal Investigator of the NIH trials: “Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)” and “Type 1 Diabetes TriaNet.”
Dr. Katz has been recognized as a researcher by being asked to serve on Scientific Review Groups at the National Institute of Diabetes, Digestive and Kidney Diseases. Ultimately, she would like this research to lead to the development of medical strategies to improve the outcomes of diabetes in youth. Dr. Katz has been elected to membership in the Lawson Wilkins Pediatric Endocrine Society, the American Diabetes Association, the Society for Pediatric Research, and is a Fellow of the American Academy of Pediatrics. She has published over 150 original articles, abstracts and chapters.
Education and Training
University of Connecticut School of Medicine, Farmington, Conn.
Pediatrics, Babies Hospital/Columbia Presbyterian Medical Center, New York, NY
Pediatric Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, PA
Pediatric Endocrinology – American Board of PediatricsPediatrics – American Board of Pediatrics
Titles and Academic Titles
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Campbell IM, Sheppard SE, Crowley TB, McGinn DE, Bailey A, McGinn MJ, Unolt M, Homans JF, Chen EY, Salmons HI, Gaynor JW, Goldmuntz E, Jackson OA2, Katz LE, Mascarenhas MR, Deeney VFX, Castelein RM, Zur KB, Elden L, Kallish S, Kolon TF, Hopkins SE, Chadehumbe MA, Lambert MP, Forbes BJ, Moldenhauer JS, Schindewolf EM1, Solot CB, Moss EM, Gur RE, Sullivan KE, Emanuel BS, Zackai EH, McDonald-McGinn DM. What is new with 22q? An update from the 22q and You Center at the Children's Hospital of Philadelphia. Am J Med Genet A. 2018 Oct;176(10):2058-2069. doi: 10.1002/ajmg.a.40637.
Bacha F1, Gidding SS2, Pyle L3, Levitt Katz L4, Kriska A5, Nadeau KJ6, Lima JAC7; Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study Group. Relationship of Cardiac Structure and Function to Cardiorespiratory Fitness and Lean Body Mass in Adolescents and Young Adults with Type 2 Diabetes J Pediatr. 2016 Oct;177:159-166.e1. doi: 10.1016/j.jpeds.2016.06.048. Epub 2016 Aug 4.
Lorraine Levitt Katz,MD, Samuel S. Gidding,MD, Fida Bacha,MD, Kathryn Hirst, PhD., Siripoom McKay, MD, Laura Pyle, PhD, and Joao A.C. Lima, MD: Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. Pediatric Diabetes 16(1): 39-47, February 2015. PMCID: 4107202
Katz LEL, Gralewski KA, Abrams P, Brar PC, Gallagher PR, Lipman TH, Brooks, LJ, Koren D: Insulin-like growth factor-I and insulin-like growth factor binding protein-1 are related to cardiovascular disease biomarkers in obese adolescents. Pediatric Diabetes December 2014.
Pamela Abrams, Lorraine Levitt Katz, Renee H. Moore, Melissa Xanthopoulos, Chanelle T. Bishop-Gilyard, Thomas A. Wadden and Robert I. Berkowitz: Threshold for Improvement in Insulin Sensitivity during an Adolescent Weight Loss Trial. The Journal of Pediatrics Page: 785-790, May 2013
TODAY Study Group, A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012 Jun 14;366(24): 2247-56. doi: 10.1056/NEJMoa1109333. Epub 2012 Apr 29.
Koren, Dorit, Katz, Lorraine E MD; Gallagher, Paul R; Brar, Preneet; Berkowitz, Robert I, Brooks, Lee: Sleep Architecture and Glucose and Insulin Homeostasis in Obese Adolescents. Diabetes Care 34, November 2011.
Anderson BJ, Abramson N, Edelstein S, Katz L et al: Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. Diabetes Care 34: 2205-2207, October 2011.
Levitt Katz LE, Magge SN, Hernandez ML, Murphy KM, McKnight HM, Lipman T. Glycemic Control in Youth with Type 2 Diabetes Declines as Early as Two Years after Diagnosis. J Pediatr. 2010 Aug 25. [Epub ahead of print]
Magge SN, Stettler N, Jawad AF, Levitt Katz LE. Increased prevalence of abnormal glucose tolerance among obese siblings of children with type 2 diabetes. J Pediatr. 2009 Apr;154(4):562-566.e1. Epub 2008 Nov 22.
Palladino AA, Sayed S, Levitt Katz LE, Gallagher PR, De León DD. Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication. J Clin Endocrinol Metab. 2009 Jan;94(1):39-44. Epub 2008 Oct 28.
Awards and Honors
2022, Philadelphia Magazine's Top Doctors in Pediatric Endocrinology
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.